A new study reveals connections between two widely used models of the disease, with findings that may reshape how scientists approach treatment. If there is one fact about Alzheimer’s disease that ...
ANX007 targets C1q to inhibit the complement cascade, reducing neuroinflammation and protecting photoreceptors in AMD and GA.
Annexon, Inc. (NASDAQ:ANNX) was able to achieve positive results from its phase 3 study for the treatment of patients with Guillain-Barré syndrome [GBS]. Matter of fact, it noted that a lower dose of ...
This story is part of a series on the current progression in Regenerative Medicine. This piece is part of a series dedicated to the eye, and it marks the second of a three-part series on dry ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Recent advances in imaging and the approval of ...
"These results clearly point to 2 main underlying etiologic mechanisms in central serous chorioretinopathy: choroidal vascular permeability/dysfunction and the ...
The story of Q32 Bio, a company that develops therapeutics for inflammatory and autoimmune diseases, started two decades ago. That's when V. Michael Holers, MD, a University of Colorado School of ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aviceda Therapeutics, a private clinical-stage biotech company focused on developing next-generation immunomodulators by harnessing the power of glycobiology to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback